An estimated four million individuals in the United States have Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
BPSD contribute significantly to the overall costs of dementia care. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Hospitalizations and emergency department (ED) visits for people with Alzheimer's disease and related disorders are of particular concern because many of these patients are physically and mentally frail, and the care delivered in these settings is costly. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The new services would cost around pound sterling 220 million extra per year nationally in England. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Down syndrome (DS) is associated with a variety of symptoms, such as incapacitating mental retardation and neurodegeneration (i.e., Alzheimer's disease), that prevent patients from leading fully independent lives. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A major tenet of gerontological practice and policy has been that community-based services relieve stress on family caregivers and delay or prevent institutionalization of frail elders. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Under Medicare Part D, senior citizens choose prescription drug insurance offered by numerous private insurers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The burden experienced by family caregivers of individuals with Alzheimer disease (AD) affects the caregivers' overall health-related quality of life (HRQOL). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a neurodegenerative disorder, marked by senile plaques composed of amyloid-β (Aβ) peptide, neurofibrillary tangles, neuronal loss and neuroinflammation. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neuropsychiatric symptoms of Alzheimer’s disease (NPS-AD) are highly prevalent and lead to poor medical and functional outcomes. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Between 1980 and 1987, the number of hospital discharges with total hip replacement (THR) increased by more than 90%, while total hospital discharges fell by more than 10%. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Compared to TM, MA increased the odds of annual wellness visits and reduced Hispanic-White disparity in annual wellness visits. 2 key findings →
Participants: 129,177 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We found that COVID patients initially experienced substantially longer hospital stays (8.3 vs 4.6 days) and higher 30-day mortality (34% vs 5%) compared to patients without COVID. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These findings highlight potential access and quality-of-care issues in PR, with implications for Medicare Advantage benchmarks. 4 key findings →
Participants: 4,965 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hispanic older adults face significant barriers to healthcare access, stemming from multiple factors: limited income, high medical costs, elevated rates of chronic disease and dementia, and greater reliance on public insurance programs, relative to other racial, ethnic, and age groups. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Obstructive sleep apnoea (OSA) is increasingly recognised as a significant risk factor for cognitive decline and dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Emerging evidence highlights the central role of peripheral immune-metabolic regulation in the pathogenesis of Alzheimer's disease and related dementias (ADRD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Amyloid-targeting antibody therapies for Alzheimer's disease require substantial diagnostic infrastructure including amyloid PET imaging, repeated MRI monitoring, and specialized clinical evaluation. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Music therapy has gained recognition as a safe, effective, and person-centered intervention that bridges neuroscience, medicine, and humanities. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Informal caregivers often seek additional support. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In this update, we examine a checklist for real-world evidence use in Medicare drug price negotiations under the Inflation Reduction Act, a review of health technology assessment reassessments across major health technology assessment agencies, and two complementary studies that used natural experiment approaches to explore the relationship between herpes zoster vaccination and reduced dementia risk. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The 2014 Improving Medicare Post-Acute Care Transformation (IMPACT) Act systemized audits of long hospice stays, and the 2016 two-tier payment system decreased daily reimbursement rates after 60 days of enrollment. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
35/100
Areas within the Appalachian region may have a greater burden of under diagnosed Alzheimer's disease and related disorders (ADRD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In 2024, 90% of Medicare Advantage (MA) enrollees were in a plan that required prior authorization of home health care. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
DLB patients had higher medication and psychosis‐related costs than DRP patients who had other dementias. 3 key findings →
Participants: 442 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 705 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- The cost of Alzheimer's disease in China and re-estimation of costs worldwide
- 2009 Alzheimer's disease facts and figures
- Quantifying diagnostic signal decay in dementia: a national study of Medicare hospitalization data
- Medical costs of Swedish nursing home residents at the end of life: a retrospective observational registry study
- Impact of fee-revision policy for gastrostomy on its implementation among older adults with dementia in Japan
- Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
- Impaired cellular copper regulation in the presence of ApoE4
- Risk Adjustment for Alzheimer Disease and Related Dementias in Medicare Advantage and Health Care Experiences
- Race and Ethnicity and Comorbidities Among Medicare Beneficiaries With Young-Onset Dementia
- Differences in Home Health Services and Outcomes Between Traditional Medicare and Medicare Advantage
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →